Santen Pharmaceutical Co (Santen Pharmaceutical Co) Interest Expense : $-15 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Santen Pharmaceutical Co's interest expense for the three months ended in Dec. 2023 was $ -5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-15 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Santen Pharmaceutical Co's Operating Income for the three months ended in Dec. 2023 was $ 77 Mil. Santen Pharmaceutical Co's Interest Expense for the three months ended in Dec. 2023 was $ -5 Mil. Santen Pharmaceutical Co's Interest Coverage for the quarter that ended in Dec. 2023 was 15.73. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Santen Pharmaceutical Co Interest Expense Historical Data

The historical data trend for Santen Pharmaceutical Co's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Interest Expense Chart

Santen Pharmaceutical Co Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Interest Expense

Get a 7-Day Free Trial

-25.92

-22.23

-13.69

-10.20

-11.22

Santen Pharmaceutical Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-8.34	-5.91	-1.19	-3.29	-4.88

Santen Pharmaceutical Co Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-15 Mil.

Santen Pharmaceutical Co (OTCPK:SNPHY) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Santen Pharmaceutical Co's Interest Expense for the three months ended in Dec. 2023 was $-5 Mil. Its Operating Income for the three months ended in Dec. 2023 was $77 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $0 Mil.

Santen Pharmaceutical Co's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	76.802	/	-4.883
	=	15.73

The higher the ratio, the stronger the company's financial strength is.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SNPHF:USA 4536:Japan SZD:Germany

Address

Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552

Website

http://www.santen.co.jp

Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood • 04-23-2020